Tumor necrosis factor (TNF) inhibitors have been widely used for the treatment of autoimmune disease since 1998, when the first biological agents were licensed in the United States.1 Several biosimilar versions are now available.2 These therapies target the TNF receptor (infliximab, adalimumab, certolizumab pegol, and golimumab) or its soluble form (etanercept) to modulate immune function.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Gelfand JM, Yazdany J. Risk of Neuroinflammatory Adverse Events With Tumor Necrosis Factor Inhibitor Treatment. JAMA Neurol. Published online May 18, 2020. doi:10.1001/jamaneurol.2020.1160
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: